Evidence map›Paper›PMID 36540610›Full record

ArticleThe EPMA journal2023

Diagnostic accuracy of autoverification and guidance system for COVID-19 RT-PCR results.

Yingmu Cai, Mengyu Liu, Zhiyuan Wu, Cuihong Tian, Song Qiu, Zhen Li, Feng Xu, Wei Li, Yan Zheng, Aijuan Xu and 2 more

Open access · hybridAbstract read
In one paragraph

Article in The EPMA journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Yingmu Cai *Joint Laboratory of Shantou University Medical College and Guangdong Hybribio Biotech Ltd, Shantou University Medical College, Shantou, 515041 Guangdong China.
Mengyu Liu *Joint Laboratory of Shantou University Medical College and Guangdong Hybribio Biotech Ltd, Shantou University Medical College, Shantou, 515041 Guangdong China.
Zhiyuan Wu *Beijing Municipal Key Laboratory of Clinical Epidemiology, School of Public Health, Capital Medical University, Beijing, 100069 China.
Cuihong Tian *Clinical Research Centre, The First Affiliated Hospital of Shantou University Medical College, Shantou, 515041 Guangdong China.
Song QiuHybribio Medical Laboratory Group Ltd, Chaozhou, 521000 Guangdong China.
Zhen LiHuman Papillomavirus Molecular Diagnostic Engineering Technology Research Centre, Chaozhou, 521000 Guangdong China.
Feng XuHuman Papillomavirus Molecular Diagnostic Engineering Technology Research Centre, Chaozhou, 521000 Guangdong China.
Wei LiJoint Laboratory of Shantou University Medical College and Guangdong Hybribio Biotech Ltd, Shantou University Medical College, Shantou, 515041 Guangdong China.
Yan ZhengDepartment of Research and Development, Guangdong Research Institute of Genetic Diagnostic and Engineering Technologies for Thalassemia, Chaozhou, 521011 Guangdong China.
Aijuan XuHuman Papillomavirus Molecular Diagnostic Engineering Technology Research Centre, Chaozhou, 521000 Guangdong China.
Longxu XieHybribio Medical Laboratory Group Ltd, Chaozhou, 521000 Guangdong China.
Xuerui TanClinical Research Centre, The First Affiliated Hospital of Shantou University Medical College, Shantou, 515041 Guangdong China.
First Affiliated Hospital of Shantou University Medical College · CNShantou University Medical College · CNCapital Medical University · CNShantou University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: To date, most countries worldwide have declared that the pandemic of COVID-19 is over, while the WHO has not officially ended the COVID-19 pandemic, and China still insists on the personalized dynamic COVID-free policy. Large-scale nucleic acid testing in Chinese communities and the manual interpretation for SARS-CoV-2 nucleic acid detection results pose a huge challenge for labour, quality and turnaround time (TAT) requirements. To solve this specific issue while increase the efficiency and accuracy of interpretation, we created an autoverification and guidance system (AGS) that can automatically interpret and report the COVID-19 reverse transcriptase-polymerase chain reaction (RT-PCR) results relaying on computer-based autoverification procedure and then validated its performance in real-world environments. This would be conductive to transmission risk prediction, COVID-19 prevention and control and timely medical treatment for positive patients in the context of the predictive, preventive and personalized medicine (PPPM). Methods: A diagnostic accuracy test was conducted with 380,693 participants from two COVID-19 test sites in China, the Hong Kong Hybribio Medical Laboratory ( Results: Among the 266,035 samples in Hong Kong, there were 16,356 (6.15%) positive, 231,073 (86.86%) negative, 18,606 (6.99%) indefinite, 231,073 (86.86%, negative) no retest required and 34,962 (13.14%, positive and indefinite) retest required; the 114,658 samples in Shanghai consisted of 76 (0.07%) positive, 109,956 (95.90%) negative, 4626 (4.03%) indefinite, 109,956 (95.90%, negative) no retest required and 4702 (4.10%, positive and indefinite) retest required. Compared to the fashioned manual interpretation, the AGS is a procedure of high accuracy [99.96% (95%CI, 99.95-99.97%) in Hong Kong and 100% (95%CI, 100-100%) in Shanghai] with perfect sensitivity [99.98% (95%CI, 99.97-99.98%) in Hong Kong and 100% (95%CI, 100-100%) in Shanghai], specificity [99.87% (95%CI, 99.82-99.90%) in Hong Kong and 100% (95%CI, 99.92-100%) in Shanghai], PPV [99.98% (95%CI, 99.97-99.99%) in Hong Kong and 100% (95%CI, 99.99-100%) in Shanghai] and NPV [99.85% (95%CI, 99.80-99.88%) in Hong Kong and 100% (95%CI, 99.90-100%) in Shanghai]. The need for manual interpretation of total samples was dramatically reduced from 100% to 13.1% and the interpretation time fell from 53 h to 26 min in Hong Kong; while the manual interpretation of total samples was decreased from 100% to 4.1% and the interpretation time dropped from 20 h to 16 min at Shanghai. Conclusions: The AGS is a procedure of high accuracy and significantly relieves both labour and time from the challenge of large-scale screening of SARS-CoV-2 using RT-PCR. It should be recommended as a powerful screening, diagnostic and predictive system for SARS-CoV-2 to contribute timely the ending of the COVID-19 pandemic following the concept of PPPM.

Indexed as

Autoverification and guidance system (AGS)COVID-19Diagnostic accuracyDynamic COVID-free policyManual interpretationPersonalized policyPredictive preventive personalized medicine (PPPM/3PM)Prevention and controlReverse transcriptase-polymerase chain reaction (RT-PCR)

Identifiers

PMID36540610
PMCPMC9755791
OpenAlexW4312093740

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.